Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
West China Hospital · Metabolic Dysfunction-Associated Steatohepatitis · Hepatic Steatosis
Phase 2 / Phase 3
Not yet recruiting
60
2026-07
Evidence dashboardStudies since 2016Updated Jul 31, 2026
MazdutideClinical Trials.
A source-linked view of every Mazdutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 37
- Recruiting
- 10
- Completed
- 18
- Terminated
- 0
- Results posted
- 1
- Average enrollment
- 263
- Countries
- 5
- Highest phase
- Phase 4
Largest indexed study
1,481 participants · NCT06143956 →Developer / research origin
Innovent Biologics
Evidence summary
Activity is not efficacy.
Mazdutide appears in 37 indexed studies: 10 recruiting, 18 completed and 1 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Mazdutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Tianjin Medical University · Type 2 Diabetes Mellitus (T2DM) · Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
Not applicable
Not yet recruiting
72
2026-07
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
China National Center for Cardiovascular Diseases · Obesity & Overweight · Coronary Heart Disease
Phase 4
Not yet recruiting
116
2026-06
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
Shandong Provincial Hospital · Prediabetes · Impaired Fasting Glucose
Phase 4
Not yet recruiting
150
2026-06
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
200
2026-06
Showing 6 of 19 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Eli Lilly · Alcohol Use Disorder
Phase 2
Completed
308
2026-07
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes · Obesity
Phase 3
Completed
349
2026-06
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight and Obesity
Phase 2
Completed
179
2026-04
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
Innovent Biologics (Suzhou) Co. Ltd. · Overweight/ Obesity
Phase 2
Completed
328
2025-11
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Adolescents With Obesity
Phase 1
Completed
36
2025-09
A Study of IBI362 in Participants With Obesity or Overweight
Innovent Biologics (Suzhou) Co. Ltd. · Obesity Or Overweight
Phase 3
Completed
610
2024-11
Showing 6 of 18 studies
No studies in this snapshot.
Full study index
Search Mazdutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
37 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 28733905 ↗Sanchez-Garrido MA, Brandt SJ, Clemmensen C, Muller TD, DiMarchi RD, Tschop MH. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017 Oct;60(10):1851-1861. doi: 10.1007/s00125-017-4354-8. Epub 2017 Jul 21.Linked from NCT07713992PMID 34713962 ↗Del Prato S, Gallwitz B, Holst JJ, Meier JJ. The incretin/glucagon system as a target for pharmacotherapy of obesity. Obes Rev. 2022 Feb;23(2):e13372. doi: 10.1111/obr.13372. Epub 2021 Oct 28.Linked from NCT07713992PMID 20957001 ↗Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschop MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010 Dec;6(12):689-97. doi: 10.1038/nrendo.2010.187. Epub 2010 Oct 19.Linked from NCT07713992PMID 31405212 ↗Al-Massadi O, Ferno J, Dieguez C, Nogueiras R, Quinones M. Glucagon Control on Food Intake and Energy Balance. Int J Mol Sci. 2019 Aug 11;20(16):3905. doi: 10.3390/ijms20163905.Linked from NCT07713992PMID 23999198 ↗van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014 Jun;38(6):784-93. doi: 10.1038/ijo.2013.162. Epub 2013 Sep 3.Linked from NCT07713992PMID 40802944 ↗Targher G, Valenti L, Byrne CD. Metabolic Dysfunction-Associated Steatotic Liver Disease. N Engl J Med. 2025 Aug 14;393(7):683-698. doi: 10.1056/NEJMra2412865. No abstract available.Linked from NCT07713992PMID 34310013 ↗Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021 Sep;23 Suppl 3:5-29. doi: 10.1111/dom.14496.Linked from NCT07713992PMID 33880754 ↗Jones B. The therapeutic potential of GLP-1 receptor biased agonism. Br J Pharmacol. 2022 Feb;179(4):492-510. doi: 10.1111/bph.15497. Epub 2021 May 20.Linked from NCT07713992
Related pages
Keep researching Mazdutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.